Drug Therapy for Rheumatoid Arthritis in Adults
Summary of Benefits: DMARD Combinations Versus Monotherapies (1 of 2)
In patients with rheumatoid arthritis who had inadequate disease control and required a change in treatment, combination therapy with a biologic disease-modifying anti-rheumatic drug (DMARD) and methotrexate (MTX) achieved greater improvements in some outcomes than either a biologic DMARD or MTX alone.
Combination therapy achieves greater improvement than biologics alone in disease activity and radiographic progression (Strength of Evidence = Moderate).
Combination therapy achieves greater improvement than MTX alone in clinical response and functional capacity (Strength of Evidence = High) as well as in quality of life (Strength of Evidence = Moderate).
- Donahue KE, Jonas D, Hansen RA, et al. Drug Therapy for Rheumatoid Arthritis in Adults: An Update. Comparative Effectiveness Review No. 55 (Prepared by the RTI International–University of North Carolina Evidence-based Practice Center under Contract No. 290-2007-10056-I). Rockville, MD: Agency for Healthcare Research and Quality; April 2012. AHRQ Publication No. 12-EHC025-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsra.cfm.
Your slide tray is being processed.